Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZENITH: zilebesiran in addition to standard of care for high-risk hypertension
jRCT2051250137Phase 3Recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Nov 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in hypertension (HTN) and cardiac morbidity comparing Zilebesiran arm with Placebo arm (2 arms). Primary endpoint: Major adverse cardiovascular events (MACE). Started Nov 2025; status: recruiting.
02
Drugs
zilebesiran
03
Conditions
hypertension (HTN)cardiac morbidity
Beyond the preview
Go deeper on jRCT2051250137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250137.